Generic Biologics Face Uphill Battle -- Part 2
Morningstar pharmaceuticals analyst Karen Andersen says generic biologics are an underdog in the U.S. market.
Brian Laegeler: I think from your perspective, you have seen some of the differences in your coverage list between traditional generics and biologics. What are your views on this subject?
Karen Andersen: Based on what we have seen so far in Europe, I think we have a little bit of an idea of how this could play out in the U.S. I think competition would really be a little bit less intense for generic biologics versus the generics that we see today on the market in the U.S., and that is for a few reasons.
Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.